PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

The information set forth below under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 1.01 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On October31, 2017 (the “Effective Date”), Puma Biotechnology, Inc. (the “Company”), entered into a loan and security agreement (the “credit facility”) with Silicon Valley Bank, as administrative and collateral agent (“SVB”), and the lenders party thereto from time to time (the “Lenders”), including Oxford Finance LLC (“Oxford”) and SVB, to which the Lenders agreed to make term loans available to the Company in an aggregate amount of $100million, consisting of (i)an aggregate amount of $50million available on the Effective Date (the “Term Loan A”) and (ii)an aggregate amount of $50million available to be drawn at the Company’s option between March31, 2018 and June30, 2018 provided the Company has achieved a specified minimum revenue milestone and no event of default is occurring (the “Term LoanB”, and together with the Term LoanA, the “Term Loans”). Proceeds from the Term Loans may be used for working capital and general business purposes. Upon the entry into the credit facility, the Company was required to pay the Lenders aggregate fees of $1,500,000, consisting of a facility fee of $750,000 and an arrangement fee of $750,000. The credit facility is secured by substantially all of the Company’s personal property other than its intellectual property. The Company also pledged 65% of the issued and outstanding capital stock of its subsidiary, Puma Biotechnology Ltd. The credit facility limits the Company’s ability to grant any interest in its intellectual property to certain permitted licenses and permitted encumbrances set forth in the agreement.

The Term Loans under the credit facility bear interest at an annual rate equal to the greater of (i)7.75% and (ii)the sum of (a)the “prime rate,” as reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (b)3.5%. The Company is required to make monthly interest-only payments on each Term Loan commencing on the first calendar day of the calendar month following the funding date of such Term Loan, and continuing on the first calendar day of each calendar month thereafter through December1, 2019 (the “Amortization Date”). Commencing on the Amortization Date, and continuing on the first calendar day of each calendar month thereafter, the Company will make consecutive equal monthly payments of principal, together with applicable interest, in arrears to each Lender, calculated to the credit facility. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on October31, 2022. Upon repayment of the Term Loans, the Company is also required to make a final payment to the Lenders equal to 7.5% of the original principal amount of Term Loans funded.

At the Company’s option, the Company may prepay the outstanding principal balance of any Term Loan in whole but not in part, subject to a prepayment fee of 2.0% of any amount prepaid if the prepayment occurs through and including the first anniversary of the funding date of such Term Loan, 1.0% of the amount prepaid if the prepayment occurs after the first anniversary of the funding date of such Term Loan through and including the second anniversary of the funding date of such Term Loan.

The credit facility includes affirmative and negative covenants applicable to the Company, its current subsidiary and any subsidiaries the Company creates in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The Company must also achieve product revenue, measured as of the last day of each fiscal quarter on a trailing 3-month basis, that is (i)greater than or equal to 70% of the Company’s revenue target set forth in its board-approved projections for the 2017 fiscal year, (ii)greater than or equal to 50% of the Company’s revenue target set forth in its board-approved projections for the 2018 fiscal year, and (iii)greater than or equal to 50% of the Company’s revenue target set forth in its board-approved projections for the 2019 fiscal year. New minimum revenue levels will be established for each subsequent fiscal year by mutual agreement of the Company, SVB, as administrative agent, and the Lenders. The negative covenants include, among others, restrictions on the Company’s transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and suffering a change in control, in each case subject to certain exceptions.

The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 5.0% and would provide SVB, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facilities, including its cash. These events of default include, among other things, the Company’s failure to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Company’s insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $500,000 and one or more judgments against us in an amount greater than $500,000 individually or in the aggregate.

On the Effective Date of the credit facility, the Company issued to SVB and Oxford, as the sole Lenders on the Effective Date, secured promissory notes in an aggregate principal amount of $50,000,000 evidencing the credit facility.

The foregoing description of the credit facility and the secured promissory notes is only a summary of the material terms thereof, does not purport to be complete and is qualified in its entirety by reference to the credit facility and the form of secured promissory note, which will be filed as exhibits to the Company’s Annual Report on Form10-K for the year ended December31, 2017.

About PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI)

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.